Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Kanglin Biotech (Hangzhou) Co. Ltd. is currently addressing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This activity is confined to 1 distinct examiner and 1 distinct art unit, reflecting a highly concentrated prosecution stage. The company's current interactions with the patent office are limited to this single administrative channel. This narrow focus suggests that the company is prioritizing a specific technological advancement rather than a broad array of diverse patent filings at this time. Such a concentrated profile allows for a streamlined management of intellectual property assets.
ALEXANDRA ROSE LIPPOLIS is the busiest examiner for the portfolio, managing 1 pending office action. With 1 pending matter assigned to this examiner, the company's immediate progress in securing patent rights is tied to the specific examination process of this individual. This concentration means that the outcome of the company's current patent efforts depends on navigating the requirements of a single examiner. Effective prosecution will require a strategy that directly addresses the technical concerns of this examiner within the Biotechnology & Pharmaceuticals field. The timeline for this portfolio is currently subject to the specific docket management of this one official.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LIPPOLIS, ALEXANDRA ROSE | 1 | 46.9% | +59.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18268251 | NUCLEIC ACID CONSTRUCT FOR AIDS GENE THERAPY | LIPPOLIS, ALEXANDRA ROSE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18268251 | NUCLEIC ACID CONSTRUCT FOR AIDS GENE THERAPY | LIPPOLIS, ALEXANDRA ROSE | — |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18268251 | NUCLEIC ACID CONSTRUCT FOR AIDS GENE THERAPY | LIPPOLIS, ALEXANDRA ROSE | 1637 | §102§103§112 | Non-Final OA | — | Pending | Jun 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial